QLH2405

Phase 1Small molecule

Qilu Pharmaceutical Co., Ltd.

QLH2405 is one of 54 small molecule programs targeting Cognitive impairment. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cognitive ImpairmentNot yet recruiting

Cognitive ImpairmentPhase 1

Not yet recruiting

Competition

Competitive Landscape

69 competitors in Cognitive Impairment

#DrugCompanyPhaseTrials

Azilect

Teva

Approved

1 2

Intropin

Marinol

Brintellix

Avandia

Epidiolex

Nimotop

AAzurity Pharmaceuticals

Approved

1 8

Bendopa

MMerz North America, Inc.

Approved

1 9

Lamictal

GGlaxo Dba Glaxosmithkline

Approved

1 10

Coumadin

AAbbott

Approved

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 1Not yet recruiting

Cognitive Impairment

NCT07489599

Clinical

Trials by Indication[1]

Cognitive impairment1 trial

A Study of QLH2405 in Healthy Participants and Participants With Mild Cognitive Impairment Due to Alzheimer's Disease and Mild Alzheimer's Disease

Not yet recruiting· Qilu Pharmaceutical Co., Ltd. logo

Qilu Pharmaceutical Co., Ltd.·Phase 1·NCT07489599·68 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for QLH2405. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — QLH2405 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for QLH2405. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Qilu Pharmaceutical Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: Qilu Pharmaceutical Co., Ltd.

QLH2405

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

Cognitive impairment1 trial

References

Drug Info

Quick Facts

Related News